Abstract: Bone metastases of malignant tumors seriously threaten the quality of life and survival benefits of patients with cancer. However, traditional anti-tumor treatments such as radiotherapy are not ideal for bone metastases and can only control the progression of local lesions. In recent years, with the progress in research on bone-targeted agents (BTA) such as bisphosphonates(BPs) and denosumab, the incidence of skeletal-related events (SREs) has considerably reduced and the survival benefit for patients with bone metastasis of some type of cancer has improved. With the breakthrough in cancer immunotherapy, exploring the application value of immune checkpoint blockade and other potential immunotherapeutic targets has brought new hope for treating cancer patients with bone metastases. This review focuses on the progress of targeted therapy and the prospect of immunotherapy for bone metastases of malignant tumors.